Get to know our clinical trials

Clinical trial to evaluate the efficacy and safety of ro7790121 in patients with moderate to severe atopic dermatitis

THE PURPOSE OF THIS TRIAL IS TO TEST WHETHER THE EXPERIMENTAL DRUG RO7790121 IS SAFE AND EFFECTIVE FOR MODERATE TO SEVERE ATOPIC DERMATITIS AND TO FIND OUT WHAT EFFECTS, GOOD OR BAD, RO7790121 HAS VERSUS PLACEBO IN ATOPIC DERMATITIS

Imagen del Dr. Rafael Salido Vallejo, especialista en Dermatología de la Clínica Universidad de Navarra. El Dr. Salido se dedica preferencialmente al cáncer cutáneo, cirugía dermatológica, cirugía de Mohs, lesiones pigmentadas, dermatoscopia y terapia fotodinámica.
Dr. Rafael Salido Vallejo [SP] Curriculum
Specialist Dermatology Department
Navarre headquarters
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO7790121 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
  • Code EudraCT: 2024-515494-95-00
  • Protocol number: CS45570
  • Promoter: Roche
  • Molecule/Drug: RO7790121

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION